Calbioreagents has released two monoclonal antibodies for Hemoglobin A1c (HbA1c).
HbA1c is an accepted marker for measuring long-term glycemic control in diabetes.
The growing epidemic of diabetes has led to the proposal that HbA1c be measured to monitor continuing therapy in diabetes patients and that HbA1c be used as a marker to help detect early diabetes.
A series of monoclonal antibodies specific for the detection of Hemoglobin A1c (HbA1c) protein has been developed by Calbioreagents' partner company Dinona (Korea).
These antibodies are available exclusively through Calbioreagents.
The HbA1c reagents include two monoclonal antibodies (clones 7F10 and 13F9) specific for HbA1c; these will pair with a specifically matched haemoglobin monoclonal (clone 7E7).
These reagents are suitable for HbA1c research or for the development of immunoassays to quantify HbA1c.
